Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05105685

Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS

Effectiveness of Recombinant Human Growth Hormone Therapy for Children With Phelan-McDermid Syndrome: An Open-label, Cross-over, Preliminary Study

Sponsor: Affiliated Hospital of Jiangnan University

Conditions Growth Hormone Treatment Phelan-McDermid Syndrome

Interventions Saline recombinant human growth hormone

Updated 4 times since 2021 Last updated: Oct 7, 2022 Started: Jun 14, 2020 Primary completion: May 12, 2021 Completion: Jun 8, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Growth Hormone Treatment and Phelan-McDermid Syndrome and is currently completed. Affiliated Hospital of Jiangnan University leads this study, which shows 4 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Nov 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2021 — Nov 2022 [monthly]

Completed PHASE1_PHASE2

First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Affiliated Hospital of Jiangnan University

Data source: Affiliated Hospital of Jiangnan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuxi, China